Evolving Pharmacologic Intervention for Methamphetamine Use Disorder: A Focus on ADAPT-2

Evolving Pharmacologic Intervention for Methamphetamine Use Disorder: A Focus on ADAPT-2

Evolving Pharmacologic Intervention for Methamphetamine Use Disorder: A Focus on ADAPT-2

Join Drs. Madhukar Trivedi and Steven Shoptaw as they discuss data from the ADAPT-2 clinical trial that  supports use of combination extended-release naltrexone and high-dose bupropion to reduce methamphetamine use in moderate to severe methamphetamine addiction. 

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Join Drs. Madhukar Trivedi and Steven Shoptaw as they discuss the evolving landscape of pharmacologic intervention for methamphetamine use disorder. Their focus will be on evidence from the ADAPT-2 clinical trial supporting the combination of extended release naltrexone and high dose bupropion to reduce methamphetamine use for patients with moderate to severe methamphetamine addiction.  These important data from ADAPT-2 offer a significant therapeutic advance for methamphetamine use disorder that can be  taken into the clinic. 

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Steven Shoptaw, PhD
    Director, UCLA Center for Behavioral and Addiction Medicine;
    Professor, UCLA  Departments of Family Medicine and Psychiatry
    and Behavioral, Los Angeles

    Other: Dr. Shoptaw receives clinical supplies for his research from Gilead Sciences, Inc., Alkermes Inc., & Indivior Inc.  

    Madhukar H. Trivedi, MD
    Professor Psychiatry, Chief of the Division of Mood Disorders;
    Founding Director of the Center for Depression Research and Clinical Care,
    UT Southwestern Medical Center, Dallas

    Consulting fees: Acadia Pharmaceuticals, Inc., Alkermes Inc, Alto Neuroscience Inc, Axsome Therapeutics, GH Research Limited, GreenLight VitalSign6 Inc, Janssen, Merck Sharp & Dohme Corp., Mind Medicine (MindMed) Inc., Neurocrine Biosciences Inc, Orexo US Inc, Otsuka, SAGE Therapeutics, Signant Health, Titan Pharmaceuticals, Inc.

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose
    • Kenyatta Crenshaw has nothing to disclose
    • Barry A. Fiedel, PhD, has nothing to disclose
    • Todd Mandell, MD has nothing to disclose
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    1. Describe the personal and societal burdens of methamphetamine use disorder in the United States 
    2. Discuss the findings from the Additive Treatment for Methamphetamine Disorder (ADAPT-2) clinical trial
    3. Formulate strategies to expand adoption of emergent pharmacologic treatment options for methamphetamine use disorder
  • Target Audience

    This activity is designed to meet the educational needs of hospitalists, nurses, physicians, physician assistants,  social workers, and anyone with interests in addiction medicine.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and National institute for Drug Abuse. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive .25 Interprofessional Continuing Education (IPCE) credit for learning and change."

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credit. Physicians should claim only credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 contact hours. Nurses should only claim credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 AAPA Category 1 CME credits. Approval is valid until September 30, 2022. PAs should only claim credit commensurate with the extent of their participation. 

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare Image

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity has received no commercial support.  Funding has been provided by the joint provider, National Institute for Drug Abuse.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.  

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free